Omalizumab v placebo for chronic asthma at up to 24 weeks*
| Outcomes | Number of trials | Steroid phase | Weighted event rates | RRR (95% CI) | NNT (CI) | |
|---|---|---|---|---|---|---|
| Omalizumab | Placebo | |||||
| *Abbreviations defined in glossary; RRR, RBI, NNT, and CI calculated from data in article using a fixed effects model. | ||||||
| ⩾1 exacerbation | 3 | Stable steroid | 14% | 26% | 46% (33 to 57) | 9 (7 to 13) |
| 3 | Steroid reduction | 18% | 33% | 44% (33 to 54) | 7 (6 to 10) | |
| RBI (CI) | ||||||
| Steroid withdrawal | 4 | Steroid reduction | 40% | 21% | 85% (58 to 116) | 6 (5 to 8) |
| ⩾50% reduction in steroid use | 4 | Steroid reduction | 76% | 56% | 35% (26 to 45) | 5 (5 to 7) |